Business, energy, technology, markets and global industry news from Business News Today

TSC-101

PharmaDeviceNews TSC-101
Representative image: Clinicians prepare a donor-derived cell therapy infusion as TScan Therapeutics’ $TCRX TSC-101 enters the Phase 3 ALLOHA-2 trial to prevent AML and MDS relapse after stem cell transplantation.
Pharma & Biotech

TSC-101 enters pivotal ALLOHA-2 trial after early donor-chimerism results

TSC-101 enters the Phase 3 ALLOHA-2 trial to test whether donor-derived TCR-T therapy can prevent AML and MDS relapse after transplant.

Read More
Pharma & Biotech

Can TScan’s TSC-101 Phase 1 data justify a pivotal leap as TCRX stock falls?

TSC-101 produced rapid donor chimerism with a commercial-ready manufacturing process, but TScan must still prove that the cellular therapy prevents post-transplant relapse.

Read More
Pharma & Biotech

TScan Therapeutics strengthens heme pipeline with dual IND clearances

TScan Therapeutics advances its ALLOHA trial and expands CD45-targeted TCR-T coverage. Discover what this means for relapse prevention.

Read More